News Releases

Worldwide revenue of $108.9 million – an increase of 16.4% year over year MASON, Ohio --(BUSINESS WIRE)--May 1, 2024-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative

MASON, Ohio --(BUSINESS WIRE)--Apr. 30, 2024-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating

MASON, Ohio --(BUSINESS WIRE)--Apr. 18, 2024-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE ®

MASON, Ohio --(BUSINESS WIRE)--Apr. 10, 2024-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter

MASON, Ohio --(BUSINESS WIRE)--Mar. 26, 2024-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating

Fourth Quarter 2023 Worldwide revenue of $106.5 million – an increase of 21.0% year over year Full Year 2023 Worldwide revenue of $399.2 million – an increase of 20.8% year over year Full Year 2023 U.S. revenue of $333.5 million – an increase of 20.3% year over year Full Year 2023 International

MASON, Ohio --(BUSINESS WIRE)--Jan. 25, 2024-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth

MASON, Ohio --(BUSINESS WIRE)--Nov. 15, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the

MASON, Ohio --(BUSINESS WIRE)--Nov. 14, 2023-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that the company has published its 2023

Worldwide revenue of $98.3 million – an increase of 18.1% year over year U.S. revenue of $81.7 million – an increase of 17.1% year over year International revenue of $16.6 million – an increase of 23.2% year over year Net loss of $9.1 million – an improvement of $3.2 million year over year Positive

MASON, Ohio --(BUSINESS WIRE)--Oct. 31, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the

MASON, Ohio --(BUSINESS WIRE)--Oct. 11, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter

Worldwide revenue of $100.9 million – an increase of 19.4% year over year U.S. revenue of $84.9 million – an increase of 19.1% year over year International revenue of $16.0 million – an increase of 20.7% year over year Net loss of $5.1 million – an improvement of $9.7 million year over year

MASON, Ohio --(BUSINESS WIRE)--Jul. 3, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release second quarter

Worldwide revenue of $93.5 million – an increase of 25.4% year over year U.S. revenue of $78.2 million – an increase of 25.6% year over year International revenue of $15.3 million – an increase of 24.4% year over year Net loss of $6.5 million – an improvement of $8.7 million year over year Positive

MASON, Ohio --(BUSINESS WIRE)--Apr. 19, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that the company will be hosting an

MASON, Ohio --(BUSINESS WIRE)--Apr. 3, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating

2022 Worldwide revenue of $330.4 million – an increase of 20.4% year over year 2022 U.S. revenue of $277.2 million – an increase of 21.0% year over year 2022 International revenue of $53.2 million – an increase of 17.7% in 2022 MASON, Ohio --(BUSINESS WIRE)--Feb. 21, 2023-- AtriCure, Inc.

MASON, Ohio --(BUSINESS WIRE)--Feb. 17, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the

Trial will evaluate the safety and effectiveness of the AtriCure AtriClip ® Left Atrial Appendage Exclusion System for stroke prevention in cardiac surgery patients MASON, Ohio --(BUSINESS WIRE)--Jan. 31, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and

MASON, Ohio --(BUSINESS WIRE)--Jan. 24, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth

MASON, Ohio --(BUSINESS WIRE)--Jan. 9, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced preliminary financial results for the fourth

MASON, Ohio --(BUSINESS WIRE)--Dec. 20, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the

Recognizes Exemplary Board Practices Related to DE&I MASON, Ohio --(BUSINESS WIRE)--Dec. 8, 2022-- AtriCure Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management,

MASON, Ohio --(BUSINESS WIRE)--Nov. 8, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will present at the 34th Annual

MASON, Ohio --(BUSINESS WIRE)--Nov. 1, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2022 financial results.

MASON, Ohio --(BUSINESS WIRE)--Oct. 25, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in upcoming

MASON, Ohio --(BUSINESS WIRE)--Oct. 11, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter

MASON, Ohio --(BUSINESS WIRE)--Sep. 6, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will host an investor education

MASON, Ohio --(BUSINESS WIRE)--Aug. 16, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the

MASON, Ohio --(BUSINESS WIRE)--Aug. 2, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2022 financial results.

MASON, Ohio --(BUSINESS WIRE)--Jul. 20, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in two

MASON, Ohio --(BUSINESS WIRE)--Jul. 12, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second

Trial will evaluate the safety and effectiveness of AtriCure’s Isolator® Synergy ™ Clamp in conjunction with endocardial catheter ablation for the treatment of Inappropriate Sinus Tachycardia MASON, Ohio --(BUSINESS WIRE)--Jun. 7, 2022-- AtriCure, Inc.

MASON, Ohio --(BUSINESS WIRE)--Jun. 1, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced the appointment of Deborah Yount as Chief

MASON, Ohio --(BUSINESS WIRE)--May 3, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2022 financial results.

New clamp is designed to improve efficiency of concomitant ablation procedures MASON, Ohio --(BUSINESS WIRE)--Apr. 12, 2022-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and

MASON, Ohio --(BUSINESS WIRE)--Apr. 11, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter

MASON, Ohio ,--(BUSINESS WIRE)--Feb. 15, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2021 and full year 2021

MASON, Ohio --(BUSINESS WIRE)--Feb. 8, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today published its inaugural Environmental, Social and

MASON, Ohio --(BUSINESS WIRE)--Feb. 1, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming 11 th Annual SVB Leerink Global

MASON, Ohio --(BUSINESS WIRE)--Jan. 25, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth

MASON, Ohio --(BUSINESS WIRE)--Jan. 10, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, announced preliminary financial results for the fourth

MASON, Ohio --(BUSINESS WIRE)--Dec. 20, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming 40 th Annual J.P.

MASON, Ohio --(BUSINESS WIRE)--Nov. 12, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Piper Sandler 33 rd Annual

MASON, Ohio --(BUSINESS WIRE)--Nov. 3, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 2021 financial results. “Our results were driven by strong growth across key

MASON, Ohio --(BUSINESS WIRE)--Oct. 26, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in upcoming investor conferences.

MASON, Ohio --(BUSINESS WIRE)--Oct. 5, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release third quarter 2021 financial results on Wednesday, November 3, 2021 .

MASON, Ohio --(BUSINESS WIRE)--Aug. 31, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Morgan Stanley 19 th Annual

MASON, Ohio --(BUSINESS WIRE)--Aug. 4, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2021 financial results. “Our second quarter results were driven by

MASON, Ohio --(BUSINESS WIRE)--Jul. 30, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Canaccord 41 st Annual Growth

MASON, Ohio --(BUSINESS WIRE)--Jul. 7, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release second quarter 2021 financial results on Wednesday, August 4, 2021 .

MASON, Ohio --(BUSINESS WIRE)--Jun. 15, 2021-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Deborah H. Telman and Maggie Yuen have been elected to its Board of Directors. Ms.

FDA approval results in the only label of its kind for more than 3 million patients in the United States , significantly expanding AtriCure’s addressable market Superiority trial showed a 29% difference in effectiveness at 12 months and a 35% difference in effectiveness at 18 months for

MASON, Ohio --(BUSINESS WIRE)--Apr. 27, 2021-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced first quarter 2021 financial results. “Our growth in the first quarter is a testament of our

MASON, Ohio --(BUSINESS WIRE)--Apr. 8, 2021-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that B. Kristine (Kris) Johnson has been named Board Chair.

MASON, Ohio --(BUSINESS WIRE)--Apr. 6, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2021 financial results on Tuesday, April 27, 2021 .

MASON, Ohio --(BUSINESS WIRE)--Mar. 2, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Oppenheimer 31 st Annual

MASON, Ohio --(BUSINESS WIRE)--Feb. 23, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced fourth quarter 2020 and full year 2020 financial results.

MASON, Ohio --(BUSINESS WIRE)--Feb. 10, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming SVB Leerink 10 th Annual

MASON, Ohio --(BUSINESS WIRE)--Feb. 2, 2021-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2020 financial results on Tuesday,

Fourth quarter 2020 worldwide revenue of $57.7 million ( U.S.   $47.4 million , International $10.3 million ) MASON, Ohio --(BUSINESS WIRE)--Jan. 11, 2021-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management,

Expansion includes adolescent patients, as young as 12 years of age, who can benefit from cryo nerve block therapy during surgical procedures involving the chest wall. MASON, Ohio --(BUSINESS WIRE)--Jan. 4, 2021-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial

MASON, Ohio --(BUSINESS WIRE)--Dec. 14, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming 39 th Annual J.P.

MASON, Ohio --(BUSINESS WIRE)--Nov. 19, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will participate in the upcoming Piper Sandler 32 nd Annual Virtual

Worldwide revenue of $54.8 million – a decrease of 3.3% year over year U.S. revenue of $44.7 million – a decrease of 3.1% year over year International revenue of $10.1 million – a decrease of 4.1% year over year MASON, Ohio --(BUSINESS WIRE)--Nov. 5, 2020-- AtriCure, Inc.

MASON, Ohio --(BUSINESS WIRE)--Oct. 26, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in two upcoming investor conferences.

MASON, Ohio --(BUSINESS WIRE)--Oct. 13, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2020 financial results on Thursday, November 5, 2020 .

MASON, Ohio --(BUSINESS WIRE)--Sep. 1, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Morgan Stanley 18 th Annual Global

MASON, Ohio --(BUSINESS WIRE)--Aug. 6, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced today that Andy Wade is stepping down from the position of Chief Financial Officer (CFO) for personal

MASON, Ohio --(BUSINESS WIRE)--Jul. 29, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in several upcoming investor conferences.

Worldwide revenue of $40.8 million – a decrease of 30.7% year over year U.S. revenue of $33.7 million – a decrease of 28.6% year over year International revenue of $7.1 million – a decrease of 39.0% year over year MASON, Ohio --(BUSINESS WIRE)--Jul. 28, 2020-- AtriCure, Inc.

MASON, Ohio --(BUSINESS WIRE)--Jul. 7, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2020 financial results on Tuesday, July 28, 2020 .

MASON, Ohio --(BUSINESS WIRE)--May 11, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the pricing of its underwritten offering of 3,977,273 shares of its common stock at a price to

MASON, Ohio --(BUSINESS WIRE)--May 11, 2020-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced it has commenced a proposed underwritten public offering in which it expects to issue and sell